Pazorest 200 Mg (Pazopanib)

Pazorest 200 mg is the formulation of Pazopanib, an oral anticancer agent that is a member of the tyrosine kinase inhibitor (TKI) category. Pazorest is predominantly utilized to treat advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). Pazopanib, being a target therapy, halts the growth of cancer cells by blocking specific enzymes that cause tumor angiogenesis and cell growth. In addition, made in strict adherence to pharmaceutical quality standards, Pazorest is a life-saving treatment for patients with certain forms of cancer.

Composition and Dosage

A single tablet of Pazorest 200 mg contains 200 milligrams of Pazopanib hydrochloride as the active pharmaceutical ingredient. In addition, is available in a film-coated tablet form and is prescribed by oncologists based on the patient’s status, weight, liver function, and tolerance to the treatment. The recommended initial dose can also vary, and patients are typically exposed to frequent monitoring to determine the best and best-tolerated dose.

Mechanism of Action

Pazorest (Pazopanib) functions by blocking and targeting some receptor tyrosine kinases (RTKs), including:

Vascular endothelial growth factor receptors (VEGFR-1, -2, -3)

Platelet-derived growth factor receptors (PDGFR-α and PDGFR-β)

C-Kit (stem cell factor receptor)

All the RTKs play a pivotal role in the angiogenic process of tumors, which is essential for tumor growth and metastasis. In addition, through the blockage of these pathways, Pazorest effectively inhibits tumors from obtaining nutrients and oxygen, thus slowing down or stopping cancer growth.

Indications

Pazorest 200 mg is used primarily in the treatment of:

Advanced Renal Cell Carcinoma (RCC) – The most common kidney cancer that has spread beyond the kidneys. Pazorest helps to delay tumor growth and manage symptoms.

Advanced Soft Tissue Sarcoma (STS) – A collection of cancers that occur in muscles, fat, nerves, and other connective tissues, especially in those who have received chemotherapy earlier.

Pazorest, in some cases, can be prescribed off-label or under investigation for other cancer diagnoses upon the discretion of the oncologist.

Instructions for Administration

The Pazorest 200 mg should be taken on an empty stomach at least 1 hour before and 2 hours after meals to ensure absorption. It should be swallowed whole with water and not crushed or chewed.

Adherence: To get drug levels effectively into the body, the drug must be taken precisely as prescribed.

Monitoring: Moreover, Laboratory tests, liver function tests, and imaging are necessary to monitor for effectiveness and early potential side effects.

Common Side Effects

Like all cancer therapy, Pazorest will cause side effects, some of which are significant enough to require medical attention. Some adverse effects include:

Fatigue or weakness

Diarrhea

Nausea and vomiting

Loss of appetite

Hypertension (high blood pressure)

Changes in hair color

Weight loss

Headache

Abdominal pain

Altered liver enzyme levels

Severe Side Effects

In some cases, more serious complications may be present, including:

Liver toxicity

Irregular heart rhythm (QT prolongation)

Blood clots

Gastrointestinal perforation or bleeding

Wound healing complications

Proteinuria (protein in urine)

Promptly report such symptoms as jaundice, chest pain, severe stomach pain, sudden dizziness, or unexpected bleeding to a healthcare provider.

Precautions and Warnings

Before commencing treatment with Pazorest 200 mg, patients should inform their doctor of any underlying conditions, such as:

Liver disease

Heart disease

Bleeding disorders

Uncontrolled hypertension

History of recent surgery or imminent surgical intervention

Pregnancy and Breastfeeding: Pazorest is contraindicated in pregnancy and lactation due to potential fetal or infant injury. Contraception must be employed during and after therapy.

Drug Interactions: Pazorest interacts with medications such as:

CYP3A4 inhibitors (e.g., ketoconazole)

CYP3A4 inducers (e.g., rifampin)

Proton pump inhibitors (e.g., omeprazole)

Other anticancer agents

Always provide a comprehensive list of drugs, supplements, or herbal medications to the doctor before starting Pazorest.

Storage Instructions

Store in a dry, cool place below 30°C (86°F)

Avoid direct sunlight and moisture exposure

Keep out of reach of children

Conclusion

Pazorest 200 mg is a valuable therapeutic agent in modern oncology. In addition, holding out hope and quality of life for patients with advanced renal cancer and soft tissue sarcoma. In addition, through the mechanism of action by inhibition of some enzymes that contribute to tumor growth, it represents a targeted therapy with measurable benefits in the field of disease control. However, due to its potential side effects and drug interactions, it must be utilized under close medical supervision with careful follow-up and supportive care. Moreover, adherence, monitoring, and coordination with the treatment team are key to its maximum effectiveness and safety for the patient.